Suleiman Daifallah, MD
Nephrology · North Kansas City, MONPI 1982897682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 356 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Calliditas Therapeutics US Inc.$1K
- Bayer$915
- Amgen$681
- Travere Therapeutics, Inc.$573
- OPKO Pharmaceuticals, LLC$409
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,83298%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,279 |
| Calliditas Therapeutics US Inc. | 37 | $1,007 |
| Bayer | 49 | $915 |
| Amgen(2 entities) | 34 | $681 |
| Travere Therapeutics, Inc. | 34 | $573 |
| OPKO Pharmaceuticals, LLC | 24 | $409 |
| Vifor Pharma, Inc. | 21 | $369 |
| Mallinckrodt Hospital Products Inc. | 11 | $362 |
| Akebia Therapeutics Inc | 19 | $356 |
| Novartis | 17 | $335 |
| GSK | 9 | $270 |
| Fresenius USA Marketing, Inc. | 14 | $226 |
| Mallinckrodt Enterprises LLC | 6 | $170 |
| ANI Pharmaceuticals, Inc. | 8 | $168 |
| Inari Medical, Inc. | 1 | $151 |
| Daiichi Sankyo Inc. | 6 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Novo Nordisk | 4 | $92 |
| Boehringer Ingelheim | 5 | $77 |
| Ascendis Pharma Endocrinology Inc | 2 | $60 |
| Medtronic | 2 | $39 |
| Ardelyx, Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $14 |
| Aurinia Pharma U.S., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$366
- TARPEYO$248
- FLOWTRIEVER CATHETER, S$151
- CT THROMBECTOMY SYSTEM KIT$151
- BENLYSTA$122
- Kerendia$120
- ACTHAR$110
How this compares
$7,960 in reported general payments places this provider in the 85th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 13 | $131,438 |
| BenlystaBelimumab | 12 | $55,215 |
| FarxigaDapagliflozin Propanediol | 26 | $19,637 |
| ClinisolParenteral Amino Acid 15% No.5 | 39 | $15,362 |
| Sevelamer Carbonate | 28 | $6,985 |
| JardianceEmpagliflozin | 11 | $5,811 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $5,744 |
| Calcium Acetate | 56 | $3,597 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 14 | $2,799 |
| ProsolParenteral Amino Acid 20% No.1 | 14 | $2,524 |
| Midodrine Hcl | 28 | $2,390 |
| Allopurinol | 241 | $1,847 |
| Calcitriol | 81 | $1,572 |
| Losartan Potassium | 148 | $972 |
| Nifedipine ErNifedipine | 48 | $939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $270 | $55,21512 claims |
| AstraZenecaFarxiga | $1,279 | $19,63726 claims |
| Boehringer IngelheimJardiance | $77 | $5,81111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 253 nephrology providers in Missouri.
Other nephrology in North Kansas City
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Bahar BastaniSt Louis$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.